• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Obstetrics

Misoprostol not linked to peripartum asthma exacerbations

byDenise PongandLeah Hawkins Bressler, MD, MPH
December 7, 2014
in Obstetrics, Pulmonology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. No patients receiving misoprostol (prostaglandin E1) reported worsening of respiratory symptoms.

2. No patients required systemic corticosteroids or increased bronchodilator use after receiving prostaglandin E1.

Evidence Rating Level: 2 (Good)

Study Rundown: Misoprostol, or prostaglandin E1 (PGE1), is commonly used to treat obstetric patients for cervical ripening, labor induction, therapeutic abortions, uterine atony and postpartum hemorrhage. It is currently unknown whether misoprostol, a commonly used synthetic PGE1, causes dyspnea and bronchospasm, which have been documented as rare adverse effects of the drug in the general population. While the American Congress of Obstetricians and Gynecologists endorses the use of misoprostol as an appropriate treatment for labor induction and postpartum hemorrhage, the organization does not provide specific information on its use in patients who are at risk for bronchoconstriction. PGE1 is typically considered a bronchodilator, but prior work has suggested that certain conditions, including pregnancy and hyperdynamic bronchial sensitivity an in asthma, can predispose an individual to bronchoconstriction following administration of PGE1. As such, the present work evaluated whether misoprostol use in peripartum women was associated with asthma exacerbations. The authors observed no evidence of increased incidence of asthma exacerbations, suggesting that PGE1 is relatively safe to use in asthmatic patients and has a low likelihood of inducing respiratory symptoms in this population.

Strengths of the study included prospective data collection following administration of PGE1. Limitations included retrospective design, dependence on proper documentation of respiratory symptoms and therapy, and a relatively small asthmatic sub-population. Additional prospective study in a larger population of asthmatic patients is needed to better characterize whether asthma exacerbations or other respiratory difficulties are a side effect of PGE1.

Click to read the study in AJOG

Relevant Reading: Asthma exacerbations during pregnancy- incidence and association with adverse pregnancy outcomes

RELATED REPORTS

Impact of COVID-19 on pediatric asthma-related healthcare utilization in New York City

Emergency department crowding negative influences outcomes for adults presenting with asthma

The Scan by 2 Minute Medicine®: Overprescribed and Understocked, A Costly Message, A Bad Wrap and Mauna Loa Erupts Again!

In-Depth [retrospective cohort]: This study evaluated respiratory complications associated with the use of PGE1 in 2629 peripartum women, particularly among women with a previous diagnosis of asthma (n=234). Outcomes of interest were moderate asthma exacerbations, defined as events necessitating a change in treatment, and severe asthma exacerbations, defined as events requiring urgent action and treatment with systemic corticosteroids.

No clinical evidence of asthma exacerbation was observed, and no patients required systemic corticosteroids or increased rescue inhaler use. Cumulative PGE1 dosages ranged from 25mcg to 4200mg and routes of administration included buccal/sublingual, rectal and vaginal.

More from this author: Non-surgical outpatient treatment for CIN shows promise, Obstetric scoring systems overestimate cases of severe sepsis, Vitamin D deficiency linked to preeclampsia

Image: PD

©2014 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. No article should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2 Minute Medicine, Inc.

Tags: asthmamisoprostol
Previous Post

Exercise improves aromatase inhibitor-induced arthralgia in breast cancer survivors

Next Post

Type I diabetes not associated with early menopause [OVADIA study]

RelatedReports

Microbe-rich environment associated with lower rates of asthma
Emergency

Impact of COVID-19 on pediatric asthma-related healthcare utilization in New York City

February 4, 2023
Evidence-based interventions for pediatric asthma successfully adapted for community health centers
Emergency

Emergency department crowding negative influences outcomes for adults presenting with asthma

December 27, 2022
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Overprescribed and Understocked, A Costly Message, A Bad Wrap and Mauna Loa Erupts Again!

December 14, 2022
Risk of autism in offspring linked to maternal pregestational diabetes and severe obesity
Chronic Disease

  Vitamin C supplementation in pregnancy improves respiratory function in children of smoking mothers at 5 years of age

December 7, 2022
Next Post
Type I diabetes not associated with early menopause [OVADIA study]

Type I diabetes not associated with early menopause [OVADIA study]

Buccal administration of dextrose gel effective for neonatal hypoglycemia

Many NICU deaths associated with potentially modifiable factors

Childhood influenza burdens healthcare despite reported increases in vaccination

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Expectant management of patent ductus arteriosus noninferior to early ibuprofen use
  • Exhaled volatile organic compounds predict bronchopulmonary dysplasia in preterm infants
  • Wellness Check: Mental Health
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options